Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Model of intraperitoneal targeted alpha-particle therapy shows post-therapy cold antibody boost (PT-CAB) enhances microtumor radiation dose and treatable tumor sizes.

Palm S, Back TA, Lindegren S, Hultborn R, Jacobsson L, Albertsson P.

J Nucl Med. 2017 Nov 24. pii: jnumed.117.201285. doi: 10.2967/jnumed.117.201285. [Epub ahead of print]

PMID:
29175984
2.

Blood flow, volume and arterio-venous passages in induced mammary tumours of the rat.

Hultborn R.

Microvasc Res. 2018 Mar;116:45-49. doi: 10.1016/j.mvr.2017.10.003. Epub 2017 Oct 22.

PMID:
29069572
3.

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.

Gustafsson-Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S.

EJNMMI Res. 2017 Dec;7(1):38. doi: 10.1186/s13550-017-0283-2. Epub 2017 Apr 24.

4.

Accelerated or conventional whole brain irradiation of malignant melanoma.

Hultborn R, Sand J, Kinhult S, Lundgren L, Stierner U, Turesson I, Albertsson P.

Acta Oncol. 2017 Jul;56(7):1021-1023. doi: 10.1080/0284186X.2016.1275777. Epub 2017 Jan 11. No abstract available.

PMID:
28075181
5.

Simulation Model of Microsphere Distribution for Selective Internal Radiation Therapy Agrees With Observations.

Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):414-421. doi: 10.1016/j.ijrobp.2016.05.007. Epub 2016 May 13.

6.

Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity.

Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P.

EJNMMI Phys. 2015 Dec;2(1):10. doi: 10.1186/s40658-015-0113-4. Epub 2015 Apr 25.

7.

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.

Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):569-76. doi: 10.1016/j.ijrobp.2015.07.005. Epub 2015 Jul 11.

PMID:
26460999
8.

Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy.

Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P.

EJNMMI Res. 2014 Dec;4(1):48. doi: 10.1186/s13550-014-0048-0. Epub 2014 Sep 16.

9.

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.

Lindegren S, Andrade LN, Bäck T, Machado CM, Horta BB, Buchpiguel C, Moro AM, Okamoto OK, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma MC, Chammas R, Hultborn R, Albertsson P.

PLoS One. 2015 May 13;10(5):e0126298. doi: 10.1371/journal.pone.0126298. eCollection 2015.

10.

Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique.

Chouin N, Lindegren S, Frost SH, Jensen H, Albertsson P, Hultborn R, Palm S, Jacobsson L, Bäck T.

J Nucl Med. 2013 Aug;54(8):1347-53. doi: 10.2967/jnumed.112.113001. Epub 2013 Jun 12.

11.

A new method to estimate parameters of the growth model for metastatic tumours.

Mehrara E, Forssell-Aronsson E, Johanson V, Kölby L, Hultborn R, Bernhardt P.

Theor Biol Med Model. 2013 May 9;10:31. doi: 10.1186/1742-4682-10-31.

12.

Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.

Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S.

Cancer Biother Radiopharm. 2013 Mar;28(2):108-14. doi: 10.1089/cbr.2012.1281. Epub 2012 Dec 11.

PMID:
23230896
13.

Differential gene expression in human fibroblasts after alpha-particle emitter (211)At compared with (60)Co irradiation.

Danielsson A, Claesson K, Parris TZ, Helou K, Nemes S, Elmroth K, Elgqvist J, Jensen H, Hultborn R.

Int J Radiat Biol. 2013 Apr;89(4):250-8. doi: 10.3109/09553002.2013.746751. Epub 2012 Dec 14.

PMID:
23134113
14.

Radiation exposure during liver surgery after treatment with (90)Y microspheres, evaluated with computer simulations and dosimeter measurements.

Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Gjertsson P, Bernhardt P.

J Radiol Prot. 2012 Dec;32(4):439-46. doi: 10.1088/0952-4746/32/4/439. Epub 2012 Oct 18.

PMID:
23079691
15.

Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At.

Cederkrantz E, Angenete E, Bäck T, Falk P, Haraldsson B, Ivarsson ML, Jensen H, Lindegren S, Hultborn R, Jacobsson L.

Cancer Biother Radiopharm. 2012 Aug;27(6):353-64. doi: 10.1089/cbr.2012.1184. Epub 2012 Jun 12.

PMID:
22690847
16.

In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.

Frost SH, Bäck T, Chouin N, Jensen H, Hultborn R, Jacobsson L, Lindegren S.

Cancer Biother Radiopharm. 2011 Dec;26(6):727-36. doi: 10.1089/cbr.2011.1046. Epub 2011 Nov 16.

PMID:
22087606
17.

Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.

Gustafsson AM, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H, Lindegren S.

Nucl Med Biol. 2012 Jan;39(1):15-22. doi: 10.1016/j.nucmedbio.2011.07.003. Epub 2011 Sep 29.

PMID:
21958859
18.

In-solution staining and arraying method for the immunofluorescence detection of γH2AX foci optimized for clinical applications.

Johansson P, Muslimovic A, Hultborn R, Fernström E, Hammarsten O.

Biotechniques. 2011 Sep;51(3):185-9. doi: 10.2144/000113738.

19.

The peptide AF-16 decreases high interstitial fluid pressure in solid tumors.

Al-Olama M, Wallgren A, Andersson B, Gatzinsky K, Hultborn R, Karlsson-Parra A, Lange S, Hansson HA, Jennische E.

Acta Oncol. 2011 Oct;50(7):1098-104. doi: 10.3109/0284186X.2011.562240. Epub 2011 Mar 4.

PMID:
21375367
20.

RBE of α-particles from (211)At for complex DNA damage and cell survival in relation to cell cycle position.

Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, Elmroth K.

Int J Radiat Biol. 2011 Apr;87(4):372-84. doi: 10.3109/09553002.2011.538127. Epub 2010 Dec 21.

PMID:
21171940
21.

[Deintellectualization of the profession].

Hultborn R.

Lakartidningen. 2010 Sep 8-14;107(36):2108. Swedish. No abstract available.

PMID:
21043204
22.

Clustered DNA damage in irradiated human diploid fibroblasts: influence of chromatin organization.

Magnander K, Hultborn R, Claesson K, Elmroth K.

Radiat Res. 2010 Mar;173(3):272-82. doi: 10.1667/RR1891.1.

PMID:
20199212
23.

Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.

Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, Jacobsson L.

Cancer Biother Radiopharm. 2009 Dec;24(6):649-58. doi: 10.1089/cbr.2009.0628.

PMID:
20025544
24.

Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components.

Angenete E, Oresland T, Falk P, Breimer M, Hultborn R, Ivarsson ML.

Acta Oncol. 2009;48(8):1144-51. doi: 10.3109/02841860903150510.

PMID:
19863222
25.

Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.

Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, Hultborn R.

J Oncol. 2010;2010:394913. doi: 10.1155/2010/394913. Epub 2009 Oct 25.

26.

Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.

Elgqvist J, Andersson H, Haglund E, Jensen H, Kahu H, Lindegren S, Warnhammar E, Hultborn R.

Cancer Biother Radiopharm. 2009 Aug;24(4):509-13. doi: 10.1089/cbr.2009.0618.

PMID:
19694586
27.

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.

J Nucl Med. 2009 Jul;50(7):1153-60. doi: 10.2967/jnumed.109.062604. Epub 2009 Jun 12.

28.

Liposarcoma: outcome based on the Scandinavian Sarcoma Group register.

Engström K, Bergh P, Gustafson P, Hultborn R, Johansson H, Löfvenberg R, Zaikova O, Trovik C, Wahlström O, Bauer HC.

Cancer. 2008 Oct 1;113(7):1649-56. doi: 10.1002/cncr.23784.

29.

Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

Palm S, Bäck T, Claesson I, Danielsson A, Elgqvist J, Frost S, Hultborn R, Jensen H, Lindegren S, Jacobsson L.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572-9.

PMID:
17869670
30.

Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology.

Engström K, Bergh P, Cederlund CG, Hultborn R, Willen H, Aman P, Kindblom LG, Meis-Kindblom JM.

Acta Oncol. 2007;46(6):838-45.

PMID:
17653909
31.

Chromosomal damage in two X-ray irradiated cell lines: influence of cell cycle stage and irradiation temperature.

Larsson DE, Gustavsson S, Hultborn R, Nygren J, Delle U, Elmroth K.

Anticancer Res. 2007 Mar-Apr;27(2):749-53.

32.

Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.

Elgqvist J, Andersson H, Bernhardt P, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1228-37.

PMID:
17145538
33.

Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.

Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.

Nucl Med Biol. 2006 Nov;33(8):1065-72. Epub 2006 Oct 4.

PMID:
17127181
34.

Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2006 Aug;47(8):1342-50.

35.

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.

Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.

Acta Oncol. 2006;45(5):590-6.

PMID:
16864174
36.

Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.

Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, Grönberg H, Hultborn R, Albertsson M, Påhlman L, Tveit KM; Nordic Gastrointestinal Tumour Adjuvant Therapy Group.

Acta Oncol. 2005;44(8):904-12. Erratum in: Acta Oncol. 2006;45(1):110.

PMID:
16332600
37.

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.

J Nucl Med. 2005 Dec;46(12):2061-7.

38.

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Nov;46(11):1907-15.

39.

Early disturbance of microvascular function precedes chemotherapy-induced intestinal injury.

Abel E, Ekman T, Warnhammar E, Hultborn R, Jennische E, Lange S.

Dig Dis Sci. 2005 Sep;50(9):1729-33.

PMID:
16133980
40.

Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.

Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Mar;46(3):464-71.

41.

[Individual physicians should not be broken by errors in administrative routines!].

Hultborn R, Weiss L.

Lakartidningen. 2004 Aug 19;101(34):2592; discussion 2592. Swedish. No abstract available.

PMID:
15446703
42.

Existential pain--an entity, a provocation, or a challenge?

Strang P, Strang S, Hultborn R, Arnér S.

J Pain Symptom Manage. 2004 Mar;27(3):241-50.

PMID:
15010102
43.

Chromatin- and temperature-dependent modulation of radiation-induced double-strand breaks.

Elmroth K, Nygren J, Stenerlöw B, Hultborn R.

Int J Radiat Biol. 2003 Oct;79(10):809-16.

PMID:
14630540
44.

Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.

Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, Palm S.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3914S-21S.

45.

(211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.

Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, Skarnemark G.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3873S-9S.

46.

Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.

Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Lindegren S, Jacobsson L.

Anticancer Res. 2003 Mar-Apr;23(2B):1219-21.

PMID:
12820374
47.

Physical performance, toxicity, and quality of life as assessed by the physician and the patient.

Luoma ML, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström P, Bengtsson NO, Hultborn R, Ostenstaad B, Mjaaland I, Valvere V, Wist E, Baldursson G, Ahigren J, Blomqvist C.

Acta Oncol. 2002;41(1):44-9.

PMID:
11990517
48.

Hypothermic modulation of doxorubicin, cisplatin and radiation cytotoxicity in vitro.

Lundgren-Eriksson L, Hultborn R, Henriksson R.

Anticancer Res. 2001 Sep-Oct;21(5):3275-80.

PMID:
11848483
49.

Radio-and chemotoxicity in mice during hypothermia.

Lundgren-Eriksson L, Palm A, Ryd W, Warnhammar E, Hultborn R.

Anticancer Res. 2001 Sep-Oct;21(5):3269-74.

PMID:
11848482
50.

Bone marrow micrometastases in patients with stage I-II localised prostate cancer.

Vagunda V, Landys K, Kankkunen JP, Vagundova M, Hultborn R, Kovarik J, Hugosson J.

Eur J Cancer. 2001 Oct;37(15):1847-52.

PMID:
11576838

Supplemental Content

Loading ...
Support Center